U.S. should review drugmakers’ opioid settlement tax breaks – House panel

This post was originally published on this site


WASHINGTON (Reuters) – The U.S. Justice and Treasury Departments should review the tax deductions four drugmakers made related to their $26 billion opioid settlement, the U.S. House Oversight and Reform Committee said in a statement on Monday.

The lawmakers, in a letter dated March 10, asked the departments to examine the tax breaks taken by Cardinal Health Inc (NYSE:CAH), McKesson Corp (NYSE:MCK), AmerisourceBergen (NYSE:ABC) Corp and Johnson &Johnson.